CeaproTSXV: CZO

Ceapro announces 2005 financial results

· Issued by Ceapro via CNW
EDMONTON, March 31 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
financial results for 2005. Highlights for the year include:-

-  Overall sales increased by 37%
-  Active ingredient sales increased by 61%
-  Gross margins increased by 10% to 58%
-  EBITDA grew to $156,000, an increase of $433,000
-  Working capital increased to $1 million
-  Assets grew by $701,000
-  Phase 1 expansion of manufacturing capacity completed
-  Technology base expanded and intellectual property value increased by
   filing 15 new patents

In summary, revenues of $2.8 million for 2005 were up from $2.4 million
in 2004. Net income improved from a loss of $398,000 in 2004 to a loss of
$57,000 or $0.00 per share in 2005.
"Overall, 2005 was a year of strong growth and investment for Ceapro,"
said Dr. Mark Redmond, Ceapro's President and CEO. "The initiatives undertaken
during the second half of 2004 resulted in increased product sales which made
2005 our best revenue year to date. The Company operated on a near break-even
basis as the Company continued to invest in market expansions, production
capacity increases, and technology development. This strategy supports
immediate growth with the benefit of increasing value and returns in the      
mid-term. 2005 was a year of strong organic growth; we will now look to
accelerate growth with new partnerships and expanded opportunities."
During the year, Ceapro also filed for 15 patents in various countries to
protect new oat processing methods, beta glucan drug delivery technology, and
new CeaProve(R) formulations.
The increased sales of our extracts and expansion of our animal health
business have been notable and analysis of Ceapro's financials (excluding the
development costs associated with CeaProve(R)) gives a positive indication of
achieving profitability.

<<
Selected Annual Information

$000s except per share data             2005          2004          2003
-------------------------------------------------------------------------
Total revenues                         2,763         2,420         2,424
Net (loss) income                        (57)         (398)          442
EBITDA                                   156          (277)          550
Basic (loss) income per share          (0.00)        (0.01)         0.01
Diluted (loss) income per share        (0.00)        (0.01)         0.01
Total assets                           2,419         1,718         1,255
Total liabilities                      1,958         1,604           873
-------------------------------------------------------------------------

Outlook

We are encouraged by strong first quarter sales and anticipate further
revenue growth throughout 2006. The expansion of sales to existing customers,
and the introduction of new products to new customers are expected to further
promote sales of both active ingredients and veterinary therapeutic products.
It is expected that the Company will undertake further expansion of
manufacturing capacity to meet the anticipated needs for increased sales.
Ceapro has made strides in the development of CeaProve(R), our diabetes
screening product. Our strategy has reached the point of forming alliances and
partnerships that will ensure market penetration in the workplace, pharmacies,
clinical laboratories, and doctor's offices. It is expected that during 2006
we will begin to generate revenues from CeaProve(R) once utilization commences
in the newly-identified screening service markets and partners commence
ordering product.
Ceapro's export sales have continued to increase despite the significant
strengthening of the Canadian dollar. While the exchange rate increase from
2004 to 2005 had a $166,000 negative effect on Ceapro's revenues, we remain
confident that enhanced production efficiencies and expanded markets will
enable us to continue to stimulate financial growth and corporate performance.
Ceapro advises that its audited financial statements for the year ended
December 31, 2005, and accompanying management's discussion and analysis, have
been filed with securities regulators and will be available on www.sedar.com.
The Company's annual report will be mailed to shareholders at the end of
April. The annual meeting of shareholders will take place in Edmonton on
June 1, 2005.

About Ceapro Inc.

Ceapro Inc. is a growth stage biotechnology company. Ceapro's core
technology is the extraction of functional, active ingredients. We will
continue to add value to our extracts by manufacturing medical and therapeutic
products, supporting the use of our extracts in products for human and animal
health and introducing health and wellness services employing our CeaProve(R)
diagnostic technology. Ceapro shares trade on the TSX Venture Exchange under
the symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 37,098,670, Recent Close: $0.28.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.



CEAPRO INC.
Consolidated Balance Sheets

                                                       As at December 31
                                                      2005          2004
-------------------------------------------------------------------------

ASSETS
CURRENT ASSETS
  Cash                                         $   438,045   $    96,266
  Accounts receivable                              982,347       425,160
  Inventories                                      228,158       345,424
  Prepaid expenses and deposits                     90,761        66,473
-------------------------------------------------------------------------
                                                 1,739,311       933,323
RESTRICTED CASH FOR THE PURCHASE OF
  PROPERTY AND EQUIPMENT                                 -        64,430

PROPERTY AND EQUIPMENT (note 3)                    679,623       720,067
-------------------------------------------------------------------------
                                               $ 2,418,934   $ 1,717,820
-------------------------------------------------------------------------
-------------------------------------------------------------------------

LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities     $   284,863   $   636,615
  Deferred revenue                                 229,676        80,000
  Current portion of convertible debentures
   (note 4)                                              -        17,510
  Callable debt (note 5)                            81,584       122,296
  Current portion of long-term debt (note 6)        33,519        28,234
  Current portion of royalties payable
   (note 7)                                        106,508       104,498
-------------------------------------------------------------------------
                                                   736,150       989,153
DEFERRED ROYALTY REVENUE (note 7(e))               457,000             -
LONG-TERM DEBT (note 6)                            436,731       471,766
EMPLOYEE FUTURE BENEFITS OBLIGATION (note 8)       159,946        76,586
ROYALTIES PAYABLE (note 7)                         167,770        66,249
-------------------------------------------------------------------------
                                                 1,957,597     1,603,754
-------------------------------------------------------------------------

SHAREHOLDERS' EQUITY
SHARE CAPITAL (note 9 (b))                       2,414,830     1,995,443
CONTRIBUTED SURPLUS (note 9(c))                    106,888       121,997
DEFICIT                                         (2,060,381)   (2,003,374)
-------------------------------------------------------------------------
                                                   461,337       114,066
-------------------------------------------------------------------------
                                               $ 2,418,934   $ 1,717,820
-------------------------------------------------------------------------
-------------------------------------------------------------------------

See accompanying notes



CEAPRO INC.
Consolidated Statements of Net Loss and Deficit

                                                 Years ended December 31
                                                      2005          2004
-------------------------------------------------------------------------

Revenue
  Sales (note 11)                              $ 2,683,433   $ 1,956,961
  Cost of goods sold                             1,123,606     1,022,831
-------------------------------------------------------------------------
  Gross margin                                   1,559,827       934,130
  Royalties, licenses, and product
   development fees                                 80,000       462,758
-------------------------------------------------------------------------
                                                 1,639,827     1,396,888
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Expenses
  General and administration                       982,887       833,346
  Royalties                                        321,692       277,149
  Sales and marketing                              255,773       130,578
  Amortization                                     161,550        91,962
  Interest on long-term debt                        41,310        10,662
  Interest on callable debt, convertible
   debentures, and other                            10,386        17,841
-------------------------------------------------------------------------
                                                 1,773,598     1,361,538
-------------------------------------------------------------------------
(Loss) income from operations                     (133,771)       35,350
-------------------------------------------------------------------------

Other income (expenses)
  Research and product development                (162,833)     (302,487)
  Loss on disposal of property and equipment             -       (12,389)
  Other income (expenses) (note 12)                239,597      (118,211)
-------------------------------------------------------------------------
                                                    76,764      (433,087)
-------------------------------------------------------------------------
Loss before income taxes                           (57,007)     (397,737)

Income taxes (note 13)
  Current                                          435,143       654,483
-------------------------------------------------------------------------
  Reduction  as a result of applying
   non-capital losses carried forward against
   the current year's taxable income              (435,143)     (654,483)
NET LOSS FOR THE YEAR                              (57,007)     (397,737)

DEFICIT, BEGINNING OF YEAR                      (2,003,374)   (1,605,637)
-------------------------------------------------------------------------
DEFICIT, END OF YEAR                           $(2,060,381)  $(2,003,374)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Net loss per share: (note 14)
  Basic                                        $     (0.00)  $     (0.01)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
  Diluted                                      $     (0.00)  $     (0.01)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

See accompanying notes



CEAPRO INC.
Consolidated Statements of Cash Flows

                                                 Years ended December 31
                                                      2005          2004
-------------------------------------------------------------------------

Operating Activities
  Net loss for the year                        $   (57,007)  $  (397,737)
  Items not affecting cash
    Amortization                                   161,550        91,962
    Loss on disposal of property and equipment           -        12,389
    Employee future benefits obligation             83,360        27,049
    Stock based compensation                        50,007        19,006
-------------------------------------------------------------------------
                                                   237,910      (247,331)
-------------------------------------------------------------------------

Changes in Non-Cash Working Capital Items
  Accounts receivable                             (557,187)       88,994
  Inventories                                      117,266      (229,868)
  Prepaid expenses and deposits                    (24,288)      (36,502)
  Accounts payable and accrued liabilities        (351,752)      252,558
  Deferred revenue                                 149,676        80,000
-------------------------------------------------------------------------
                                                  (666,285)      155,182
-------------------------------------------------------------------------
                                                  (428,375)      (92,149)
-------------------------------------------------------------------------

Investing Activities
  Purchase of property and equipment              (121,106)     (477,230)
  Restricted cash for the purchase of property
   and equipment                                    64,430       (64,430)
-------------------------------------------------------------------------
                                                   (56,676)     (541,660)
-------------------------------------------------------------------------

Financing Activities
  Repayment of long-term debt                      (29,750)      (44,832)
  Proceeds from long-term debt                           -       500,000
  Repayment of callable debt                       (40,712)      (37,387)
  Repayment of convertible debentures              (20,000)      (10,000)
  Proceeds from issuance of share capital          238,817       111,131
  Proceeds from exercise of stock options          117,944             -
  Proceeds from royalty interest unit offering     457,000             -
  Increase (decrease) in royalties payable         103,531       (37,280)
-------------------------------------------------------------------------
                                                   826,830       481,632
-------------------------------------------------------------------------

Increase (decrease) in cash                        341,779      (152,177)
Cash at beginning of year                           96,266       248,443
-------------------------------------------------------------------------
CASH AT END OF YEAR                            $   438,045   $    96,266
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Supplementary information:
  Interest paid                                $    51,906   $    26,300
  Royalties paid                               $   218,161   $   312,502

See accompanying notes

>>


Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases